TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

Alumis Inc. announced it will report topline data from the Phase 3 ONWARD clinical program evaluating envudeucitinib for moderate-to-severe plaque psoriasis on January 6, 2026, at 8:00 a.m. ET. The company will host a conference call and webcast to discuss the results.

Insights
ALBpA   positive

Gained 14.37% with multiple analysts raising price targets


ALMS   positive

The company is announcing Phase 3 topline data results for a key pipeline asset (envudeucitinib), which represents significant clinical progress. The announcement of data readout is typically viewed positively as it demonstrates advancement toward potential commercialization, though the actual efficacy/safety results remain unknown until disclosed.